These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2448703)

  • 1. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats.
    Stone DM; Hanson GR; Gibb JW
    Neuropharmacology; 1987 Nov; 26(11):1657-61. PubMed ID: 2448703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity.
    Johnson M; Stone DM; Bush LG; Hanson GR; Gibb JW
    Eur J Pharmacol; 1989 Feb; 161(2-3):181-8. PubMed ID: 2470597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives.
    Stone DM; Johnson M; Hanson GR; Gibb JW
    Eur J Pharmacol; 1987 Feb; 134(2):245-8. PubMed ID: 2883012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat.
    Stone DM; Merchant KM; Hanson GR; Gibb JW
    Neuropharmacology; 1987 Dec; 26(12):1677-83. PubMed ID: 2893986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat.
    Johnson M; Hanson GR; Gibb JW
    Biochem Pharmacol; 1987 Dec; 36(23):4085-93. PubMed ID: 2446629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue.
    Schmidt CJ; Wu L; Lovenberg W
    Eur J Pharmacol; 1986 May; 124(1-2):175-8. PubMed ID: 2424776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine.
    Stone DM; Johnson M; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1988 Oct; 247(1):79-87. PubMed ID: 2902215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA).
    Slikker W; Ali SF; Scallet AC; Frith CH; Newport GD; Bailey JR
    Toxicol Appl Pharmacol; 1988 Jul; 94(3):448-57. PubMed ID: 2456631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons.
    Battaglia G; Yeh SY; De Souza EB
    Pharmacol Biochem Behav; 1988 Feb; 29(2):269-74. PubMed ID: 2452449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain.
    Gibb JW; Stone DM; Stahl DC; Hanson GR
    NIDA Res Monogr; 1987; 76():316-21. PubMed ID: 2449619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons.
    Schmidt CJ; Taylor VL
    Eur J Pharmacol; 1988 Oct; 156(1):121-31. PubMed ID: 2463176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.
    Stone DM; Stahl DC; Hanson GR; Gibb JW
    Eur J Pharmacol; 1986 Aug; 128(1-2):41-8. PubMed ID: 2875893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
    Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
    J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat.
    Johnson M; Letter AA; Merchant K; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1988 Mar; 244(3):977-82. PubMed ID: 2472482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA).
    Lowy MT; Nash JF; Meltzer HY
    Eur J Pharmacol; 1989 Apr; 163(1):157-61. PubMed ID: 2472965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats.
    Schmidt CJ; Abbate GM; Black CK; Taylor VL
    J Pharmacol Exp Ther; 1990 Nov; 255(2):478-83. PubMed ID: 1978728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine.
    Schmidt CJ; Black CK; Taylor VL
    Eur J Pharmacol; 1990 May; 181(1-2):59-70. PubMed ID: 1974858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat.
    Hekmatpanah CR; McKenna DJ; Peroutka SJ
    Neurosci Lett; 1989 Sep; 104(1-2):178-82. PubMed ID: 2573011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine.
    Johnson M; Mitros K; Stone DM; Zobrist R; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1992 May; 261(2):586-91. PubMed ID: 1374469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys.
    Kleven MS; Woolverton WL; Seiden LS
    Brain Res; 1989 May; 488(1-2):121-5. PubMed ID: 2472850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.